What is Regeneron Pharmaceuticals Inc's earnings per share (EPS)?

Regeneron Pharmaceuticals Inc (REGN) reported diluted earnings per share of $41.48 for fiscal year 2025. This represents a 8.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Regeneron Pharmaceuticals Inc (REGN) Financials

REGN

Trailing 12 months to June 30, 2026

Revenue $15.5B +9.3% YoY

Net Income $4.3B -2.9% YoY

EPS (Diluted) $40.47 +1.9% YoY

Free Cash Flow $3.8B -2.4% YoY

Market Cap $76.1B as of Oct 9, 2026

Price / Sales 4.9x on $15.5B revenue, trailing 12 months to June 30, 2026

Price / Earnings 17.6x on $4.3B net income, trailing 12 months to June 30, 2026

Price / Book 2.4x on $31.7B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the REGN SEC filings page.

Regeneron Pharmaceuticals Inc (REGN) reported $15.5B in revenue over the twelve months to Jun 30, 2026, up 9.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI REGN FY2025 2026-10-03

Regeneron remains highly profitable and lightly leveraged, but rising R&D intensity is compressing operating margins while cash generation stays resilient.

Cash conversion diverged from operating performance in FY2025: operating cash flow increased 12.6% while operating income declined 10.3%. Free cash flow margin recovered to 28.4% from 25.8% despite higher capital spending, indicating that cash generation improved without a corresponding improvement in operating profitability.

R&D intensity rose by roughly four percentage points year over year, coinciding with a 3.2-point operating-margin contraction. The cost structure therefore reflects heavier ongoing reinvestment, while net profitability remained comparatively stable rather than following operating income lower.

The balance sheet is funded predominantly by equity: debt-to-equity was 0.1x and current assets covered current liabilities by 4.1x in FY2025. That conservative financing posture coexisted with buybacks of $3.4B and dividends of $370M, so capital returns occurred alongside continued asset growth rather than rising leverage.

Financial Health Signals

Financial Health Score 78/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Regeneron Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Regeneron Pharmaceuticals Inc has an operating margin of 24.9%, meaning the company retains $25 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power. This is down from 28.1% the prior year.

Growth

Regeneron Pharmaceuticals Inc's revenue grew a modest 1.0% year-over-year to $14.3B. This slow but positive growth earns a score of 48/100.

Leverage

Regeneron Pharmaceuticals Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.13, Regeneron Pharmaceuticals Inc holds $4.13 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.

Cash Flow

Regeneron Pharmaceuticals Inc converts 28.4% of revenue into free cash flow ($4.1B). This strong cash generation earns a score of 93/100.

Returns

Regeneron Pharmaceuticals Inc's ROE of 14.4% shows moderate profitability relative to equity, earning a score of 64/100. This is down from 15.0% the prior year.

Altman Z-Score Safe

7.20

Regeneron Pharmaceuticals Inc scores 7.20, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($76.1B) relative to total liabilities ($9.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Regeneron Pharmaceuticals Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.11x

For every $1 of reported earnings, Regeneron Pharmaceuticals Inc generates $1.11 in operating cash flow ($5.0B OCF vs $4.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

81.69x

Regeneron Pharmaceuticals Inc earns $81.69 in operating income for every $1 of interest expense ($3.6B vs $43.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.3B

YoY+16.7%

QoQ+19.0%

5Y CAGR-3.5%

10Y CAGR+13.5%

Regeneron Pharmaceuticals Inc generated $4.3B in revenue in Q2 2026. This represents an increase of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 19.0%.

EBITDA

$1.4B

YoY+16.7%

QoQ+85.0%

5Y CAGR-16.1%

Regeneron Pharmaceuticals Inc's EBITDA was $1.4B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 85.0%.

Net Income

$1.3B

YoY-6.8%

QoQ+78.3%

5Y CAGR-16.0%

10Y CAGR+20.8%

Regeneron Pharmaceuticals Inc reported $1.3B in net income in Q2 2026. This represents a decrease of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 78.3%.

EPS (Diluted)

$12.23

YoY-4.5%

QoQ+81.2%

5Y CAGR-15.2%

10Y CAGR+21.9%

Regeneron Pharmaceuticals Inc earned $12.23 per diluted share (EPS) in Q2 2026. This represents a decrease of 4.5% from the same quarter a year earlier. Against the prior quarter it is up 81.2%.

Cash & Balance Sheet

Free Cash Flow

$572.8M

YoY-38.1%

QoQ-32.5%

5Y CAGR+3.7%

10Y CAGR+8.2%

Regeneron Pharmaceuticals Inc generated $572.8M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 38.1% from the same quarter a year earlier. Against the prior quarter it is down 32.5%.

Cash & Debt

$2.5B

YoY+23.0%

QoQ-17.1%

5Y CAGR+3.5%

10Y CAGR+14.3%

Regeneron Pharmaceuticals Inc held $2.5B in cash against $2.0B in long-term debt as of Q2 2026.

Dividends Per Share

$0.94

YoY+6.8%

QoQ0.0%

Regeneron Pharmaceuticals Inc paid $0.94 per share in dividends in Q2 2026. This represents an increase of 6.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

Diluted avg 106M

Regeneron Pharmaceuticals Inc had a weighted average of 106M diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Margins & Returns

Operating Margin

30.1%

YoY+0.8pp

QoQ+12.3pp

5Y change-35.0pp

Regeneron Pharmaceuticals Inc's operating margin was 30.1% in Q2 2026, reflecting core business profitability. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.3 percentage points.

Net Margin

30.2%

YoY-7.6pp

QoQ+10.1pp

5Y change-30.1pp

10Y change+14.1pp

Regeneron Pharmaceuticals Inc's net profit margin was 30.2% in Q2 2026, showing the share of revenue converted to profit. This is down 7.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.1 percentage points.

Return on Equity

4.1%

YoY-0.6pp

QoQ+1.8pp

5Y change-16.4pp

10Y change-0.7pp

Regeneron Pharmaceuticals Inc's ROE was 4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.6B

YoY+14.8%

QoQ+5.7%

5Y CAGR+18.0%

Regeneron Pharmaceuticals Inc invested $1.6B in research and development in Q2 2026. This represents an increase of 14.8% from the same quarter a year earlier. Against the prior quarter it is up 5.7%.

Share Buybacks

$1.2B

YoY+10.2%

QoQ+47.2%

5Y CAGR+30.8%

Regeneron Pharmaceuticals Inc spent $1.2B on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 10.2% from the same quarter a year earlier. Against the prior quarter it is up 47.2%.

Capital Expenditures

$240.2M

YoY+9.7%

QoQ+4.2%

5Y CAGR+10.1%

10Y CAGR+5.6%

Regeneron Pharmaceuticals Inc invested $240.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 9.7% from the same quarter a year earlier. Against the prior quarter it is up 4.2%.

REGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REGN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$15.5B	$14.3B+1.0%	$14.2B+8.3%	$13.1B+7.8%	$12.2B-24.3%	$16.1B+89.1%	$8.5B+29.6%	$6.6B+27.4%	$5.1B-12.4%	$5.9B+20.8%	$4.9B+18.4%	$4.1B+45.5%	$2.8B+34.0%	$2.1B+52.7%	$1.4B+209.2%	$445.8M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$402.8M+69.6%	$237.5M+17.3%	$202.5M+4.1%	$194.6M-19.5%	$241.7M+87.3%	$129.0M+9.3%	$118.0M+40.7%	$83.9M+1890.7%	$4.2M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.2B+25.4%	$4.9B-13.4%	$5.7B+21.5%	$4.7B+20.8%	$3.9B+43.5%	$2.7B+35.4%	$2.0B+53.5%	$1.3B+193.1%	$441.6M
R&D Expenses	$6.3B	$5.9B+14.0%	$5.1B+15.6%	$4.4B+23.6%	$3.6B+25.6%	$2.9B+8.1%	$2.6B+8.0%	$2.5B+66.8%	$1.5B-29.2%	$2.1B+1.1%	$2.1B+26.6%	$1.6B+27.5%	$1.3B+47.8%	$859.9M+37.5%	$625.6M+18.1%	$529.5M
SG&A Expenses	$2.7B	$2.7B-8.6%	$3.0B+12.3%	$2.6B+24.4%	$2.1B+15.9%	$1.8B+35.6%	$1.3B+0.3%	$1.3B+19.0%	$1.1B-14.6%	$1.3B+12.1%	$1.2B+40.4%	$838.5M+61.5%	$519.3M+49.9%	$346.4M+64.4%	$210.8M+79.7%	$117.3M
Operating Income	$3.8B	$3.6B-10.3%	$4.0B-1.4%	$4.0B-14.6%	$4.7B-47.0%	$8.9B+150.1%	$3.6B+61.9%	$2.2B-12.8%	$2.5B+21.9%	$2.1B+56.3%	$1.3B+6.3%	$1.3B+51.9%	$823.9M+10.9%	$743.0M+62.3%	$457.7M+323.1%	-$205.2M
EBITDA	N/A	$4.1B-7.9%	$4.5B+0.1%	$4.5B-12.1%	$5.1B-45.0%	$9.2B+142.2%	$3.8B+57.5%	$2.4B-9.8%	$2.7B+20.6%	$2.2B+55.0%	$1.4B+8.2%	$1.3B+51.4%	$876.6M+11.8%	$784.3M+58.5%	$494.7M+384.2%	-$174.1M
Interest Expense	$55.4M	$43.8M-20.7%	$55.2M-24.4%	$73.0M+22.9%	$59.4M+3.7%	$57.3M+0.7%	$56.9M+88.4%	$30.2M+7.1%	$28.2M+12.4%	$25.1M+248.6%	$7.2M-49.4%	$14.2M-61.9%	$37.4M-19.5%	$46.4M+2.5%	$45.3M+112.9%	$21.3M
Income Tax	$837.3M	$725.8M+97.6%	$367.3M+49.5%	$245.7M-52.8%	$520.4M-58.4%	$1.3B+320.8%	$297.2M-5.1%	$313.3M+187.2%	$109.1M-87.6%	$880.0M+102.6%	$434.3M-26.3%	$589.0M+39.2%	$423.1M+49.7%	$282.6M+184.2%	-$335.8M-29568.6%	-$1.1M
Net Income	$4.3B	$4.5B+2.1%	$4.4B+11.6%	$4.0B-8.9%	$4.3B-46.3%	$8.1B+129.9%	$3.5B+66.0%	$2.1B-13.4%	$2.4B+104.0%	$1.2B+33.8%	$895.5M+40.8%	$636.1M+88.1%	$338.1M-18.3%	$413.7M-44.9%	$750.3M+438.3%	-$221.8M
EPS (Basic)	N/A	$43.07+5.3%	$40.90+10.4%	$37.05-8.5%	$40.51-47.0%	$76.40+134.0%	$32.65+68.5%	$19.38-14.4%	$22.65+101.0%	$11.27+31.8%	$8.55+38.6%	$6.17+83.6%	$3.36-20.6%	$4.23-46.6%	$7.92+423.3%	-$2.45
EPS (Diluted)	$40.47	$41.48+8.2%	$38.34+10.3%	$34.77-9.0%	$38.22-46.9%	$71.97+135.8%	$30.52+65.3%	$18.46-13.3%	$21.29+105.9%	$10.34+34.3%	$7.70+39.5%	$5.52+85.2%	$2.98-19.9%	$3.72-44.9%	$6.75+375.5%	-$2.45
Diluted Shares (Avg)	N/A	109M-5.6%	115M+1.2%	114M+0.2%	114M+1.2%	112M-2.5%	115M+0.4%	115M-0.2%	115M-0.9%	116M-0.3%	116M+0.9%	115M+1.6%	113M+1.9%	111M-3.5%	115M+27.3%	91M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$4.3B+16.7%	$3.6B+19.0%	$3.9B+2.5%	$3.8B+0.9%	$3.7B+3.6%	$3.0B-3.7%	$3.8B+10.3%	$3.7B+10.6%
R&D Expenses	$1.6B+14.8%	$1.5B+16.3%	$1.6B+15.2%	$1.5B+16.0%	$1.4B+18.5%	$1.3B+6.3%	$1.4B+20.0%	$1.3B+18.2%
SG&A Expenses	$662.1M+4.4%	$647.7M+2.3%	$775.0M-2.2%	$657.8M-7.9%	$634.2M-16.4%	$633.0M-8.1%	$792.2M+7.4%	$714.4M+11.5%
Operating Income	$1.3B+19.8%	$642.9M+8.7%	$879.9M-11.1%	$1.0B-12.9%	$1.1B+0.9%	$591.7M-21.3%	$990.2M+1.8%	$1.2B+6.2%
EBITDA	$1.4B+16.7%	$766.1M+6.6%	$1.0B-8.2%	$1.2B-10.6%	$1.2B+2.0%	$718.6M-17.0%	$1.1B+2.8%	$1.3B+7.0%
Interest Expense	$11.0M+205.6%	$12.9M+48.3%	$12.2M+16.2%	$19.3M+39.9%	$3.6M-75.7%	$8.7M-46.0%	$10.5M-42.6%	$13.8M-22.5%
Income Tax	$230.9M+81.7%	$104.0M+8.0%	$199.1M+392.8%	$303.3M+99.0%	$127.1M-35.1%	$96.3M+552.1%	$40.4M+436.7%	$152.4M+48.0%
Net Income	$1.3B-6.8%	$727.2M-10.1%	$844.6M-8.0%	$1.5B+8.9%	$1.4B-2.8%	$808.7M+12.0%	$917.7M-20.9%	$1.3B+33.0%
EPS (Basic)	$12.62-4.7%	$6.99-7.8%	$8.24-3.5%	$14.09+13.6%	$13.24-0.1%	$7.58+13.1%	$8.54-21.6%	$12.40+30.8%
EPS (Diluted)	$12.23-4.5%	$6.75-7.2%	$7.87-3.0%	$13.62+18.0%	$12.81+3.2%	$7.27+15.9%	$8.11-20.5%	$11.54+29.8%
Diluted Shares (Avg)	106M-2.4%	108M-3.1%	N/A	107M-7.7%	109M-5.9%	111M-3.4%	N/A	116M+2.5%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

REGN Balance Sheet

REGN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$40.6B+7.4%	$37.8B+14.1%	$33.1B+13.2%	$29.2B+14.9%	$25.4B+48.2%	$17.2B+15.9%	$14.8B+26.2%	$11.7B+33.9%	$8.8B+25.7%	$7.0B+24.3%	$5.6B+46.2%	$3.8B+30.0%	$3.0B+41.8%	$2.1B+57.2%	$1.3B
Current Assets	$18.0B-3.4%	$18.7B-4.2%	$19.5B+22.6%	$15.9B+13.3%	$14.0B+43.3%	$9.8B+27.2%	$7.7B+19.3%	$6.4B+48.7%	$4.3B+36.3%	$3.2B+9.1%	$2.9B+39.8%	$2.1B+16.0%	$1.8B+49.0%	$1.2B+81.1%	$665.8M
Cash & Equivalents	$3.1B+25.3%	$2.5B-8.9%	$2.7B-12.1%	$3.1B+7.6%	$2.9B+31.5%	$2.2B+35.6%	$1.6B+10.2%	$1.5B+80.6%	$812.7M+51.8%	$535.2M-33.9%	$809.1M+24.7%	$648.7M+21.1%	$535.6M+132.6%	$230.3M-52.4%	$483.6M
Short-Term Investments	$5.5B-15.9%	$6.5B-19.6%	$8.1B+75.0%	$4.6B+65.0%	$2.8B+101.6%	$1.4B-12.7%	$1.6B+18.9%	$1.3B+124.9%	$596.8M+18.5%	$503.5M+113.2%	$236.1M-6.2%	$251.8M+59.0%	$158.4M+103.5%	$77.8M+79.6%	$43.3M
Inventory	$3.2B+3.7%	$3.1B+19.6%	$2.6B+7.4%	$2.4B+23.1%	$2.0B+1.8%	$1.9B+35.4%	$1.4B+23.0%	$1.2B+58.5%	$726.1M+81.8%	$399.4M+67.4%	$238.6M+85.1%	$128.9M+83.2%	$70.4M+145.7%	$28.6M+72.4%	$16.6M
Accounts Receivable	$5.7B-7.6%	$6.2B+9.6%	$5.7B+6.4%	$5.3B-11.7%	$6.0B+46.7%	$4.1B+95.9%	$2.1B+21.8%	$1.7B+12.0%	$1.5B+14.5%	$1.3B+16.6%	$1.2B+55.9%	$739.4M-6.1%	$787.1M+32.7%	$593.2M+1999.6%	$28.3M
Long-Term Investments	$10.3B+15.3%	$8.9B+64.9%	$5.4B-18.1%	$6.6B-3.6%	$6.8B+118.1%	$3.1B-3.7%	$3.3B+85.6%	$1.8B+18.1%	$1.5B+72.0%	$864.3M+36.7%	$632.2M+37.4%	$460.2M+18.0%	$389.9M+43.7%	$271.2M-1.7%	$275.9M
Total Liabilities	$9.3B+10.7%	$8.4B+18.3%	$7.1B+8.5%	$6.6B-1.7%	$6.7B+8.6%	$6.1B+65.2%	$3.7B+24.8%	$3.0B+13.6%	$2.6B+3.8%	$2.5B+29.2%	$2.0B+51.8%	$1.3B+28.9%	$998.9M+19.6%	$835.1M-0.3%	$837.9M
Current Liabilities	$4.4B+10.8%	$3.9B+15.2%	$3.4B+9.0%	$3.1B-20.1%	$3.9B+45.8%	$2.7B+28.7%	$2.1B+45.3%	$1.4B+27.1%	$1.1B-8.5%	$1.2B+53.1%	$811.2M+23.9%	$654.7M+119.1%	$298.8M+82.7%	$163.6M+10.3%	$148.3M
Non-Current Liabilities	$4.9B+10.6%	$4.5B+21.1%	$3.7B+8.1%	$3.4B+24.7%	$2.7B-20.6%	$3.4B+112.5%	$1.6B+5.5%	$1.5B+3.3%	$1.5B+15.7%	$1.3B+12.2%	$1.1B+80.7%	$632.8M-9.6%	$700.1M+4.3%	$671.6M-2.6%	$689.6M
Long-Term Debt	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$31.3B+6.5%	$29.4B+13.0%	$26.0B+14.6%	$22.7B+20.8%	$18.8B+70.2%	$11.0B-0.6%	$11.1B+26.6%	$8.8B+42.5%	$6.1B+38.1%	$4.4B+21.7%	$3.7B+43.3%	$2.6B+29.8%	$2.0B+56.3%	$1.3B+158.7%	$485.7M
Retained Earnings	$35.8B+13.0%	$31.7B+16.2%	$27.3B+17.0%	$23.3B+22.9%	$19.0B+74.1%	$10.9B+47.6%	$7.4B+40.5%	$5.3B+78.3%	$2.9B+68.6%	$1.7B+105.0%	$852.7M+293.6%	$216.6M+333.7%	-$92.7M+82.1%	-$517.1M+59.2%	-$1.3B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$41.7B+9.2%	$40.9B+8.9%	$40.6B+7.4%	$40.2B+7.3%	$38.2B+5.9%	$37.5B+9.2%	$37.8B+14.1%	$37.4B+16.4%
Current Assets	$18.4B+9.4%	$18.2B+3.6%	$18.0B-3.4%	$18.0B-7.0%	$16.9B-11.6%	$17.6B-6.9%	$18.7B-4.2%	$19.3B+3.7%
Cash & Equivalents	$2.5B+23.0%	$3.0B-4.1%	$3.1B+25.3%	$2.5B+24.6%	$2.0B+3.9%	$3.1B+18.8%	$2.5B-8.9%	$2.0B-6.5%
Short-Term Investments	$5.5B+1.2%	$5.8B+10.1%	$5.5B-15.9%	$5.9B-23.7%	$5.5B-30.6%	$5.3B-33.6%	$6.5B-19.6%	$7.8B+0.3%
Inventory	$3.1B-3.8%	$3.1B-2.8%	$3.2B+3.7%	$3.3B+7.8%	$3.2B+11.6%	$3.2B+17.6%	$3.1B+19.6%	$3.0B+17.8%
Accounts Receivable	$6.6B+17.0%	$5.7B+3.1%	$5.7B-7.6%	$5.7B-6.9%	$5.6B-1.9%	$5.6B+6.5%	$6.2B+9.6%	$6.1B+9.4%
Long-Term Investments	$9.8B-2.3%	$9.8B+5.5%	$10.3B+15.3%	$10.3B+21.1%	$10.1B+30.2%	$9.3B+32.9%	$8.9B+64.9%	$8.5B+46.9%
Total Liabilities	$10.0B+21.0%	$9.4B+15.8%	$9.3B+10.7%	$9.2B+13.5%	$8.3B+5.1%	$8.2B+10.6%	$8.4B+18.3%	$8.1B+11.8%
Current Liabilities	$5.5B+50.8%	$5.1B+43.2%	$4.4B+10.8%	$4.4B+20.9%	$3.7B+4.5%	$3.6B-0.4%	$3.9B+15.2%	$3.7B+1.7%
Non-Current Liabilities	$4.5B-2.7%	$4.3B-5.5%	$4.9B+10.6%	$4.8B+7.4%	$4.6B+5.5%	$4.6B+20.9%	$4.5B+21.1%	$4.5B+21.7%
Long-Term Debt	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%	$2.0B+0.1%
Total Equity	$31.7B+5.9%	$31.4B+6.9%	$31.3B+6.5%	$31.0B+5.6%	$29.9B+6.1%	$29.4B+8.9%	$29.4B+13.0%	$29.3B+17.8%
Retained Earnings	$37.6B+11.7%	$36.4B+12.5%	$35.8B+13.0%	$35.0B+14.0%	$33.7B+14.5%	$32.4B+15.7%	$31.7B+16.2%	$30.8B+17.8%

Not reported in any period shown, so not listed: Goodwill.

REGN Cash Flow Statement

REGN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.7B	$5.0B+12.6%	$4.4B-3.8%	$4.6B-8.4%	$5.0B-29.2%	$7.1B+170.5%	$2.6B+7.7%	$2.4B+10.7%	$2.2B+67.9%	$1.3B-12.0%	$1.5B+11.7%	$1.3B+76.9%	$752.4M+27.8%	$588.6M+888.8%	-$74.6M+47.3%	-$141.7M
Depreciation & Amortization	N/A	$543.7M+12.6%	$482.9M+14.7%	$421.0M+23.3%	$341.4M+19.3%	$286.2M+21.3%	$235.9M+12.2%	$210.3M+41.9%	$148.2M+1.9%	$145.5M+39.0%	$104.7M+39.8%	$74.9M+42.2%	$52.7M+27.9%	$41.2M+11.5%	$36.9M+18.8%	$31.1M
Stock-Based Compensation	N/A	$993.7M+1.1%	$982.8M+11.1%	$885.0M+22.1%	$725.0M+20.5%	$601.7M+39.3%	$432.0M-7.0%	$464.3M+8.6%	$427.4M-15.8%	$507.3M-9.4%	$559.9M+22.0%	$459.0M+42.7%	$321.8M+49.4%	$215.4M+128.7%	$94.2M+67.9%	$56.1M
Capital Expenditures	$920.9M	$898.4M+18.9%	$755.9M+5.2%	$718.6M+21.8%	$590.1M+6.9%	$551.9M-10.2%	$614.6M+43.1%	$429.6M+12.1%	$383.1M+40.5%	$272.6M-46.7%	$511.9M-24.5%	$677.9M+103.6%	$333.0M+113.0%	$156.3M+216.8%	$49.3M-13.8%	$57.2M
Free Cash Flow	$3.8B	$4.1B+11.3%	$3.7B-5.4%	$3.9B-12.4%	$4.4B-32.2%	$6.5B+225.9%	$2.0B+0.2%	$2.0B+10.4%	$1.8B+75.2%	$1.0B+6.2%	$974.0M+49.2%	$652.8M+55.7%	$419.4M-3.0%	$432.3M+448.7%	-$124.0M+37.7%	-$198.9M
Investing Cash Flow	-$704.2M	-$629.1M+74.5%	-$2.5B+22.5%	-$3.2B+15.8%	-$3.8B+29.7%	-$5.4B-7527.1%	-$70.6M+96.5%	-$2.0B-38.6%	-$1.5B-45.5%	-$1.0B+4.0%	-$1.0B-15.3%	-$907.6M-115.7%	-$420.8M-18.4%	-$355.5M-338.4%	-$81.1M-163.1%	$128.5M
Financing Cash Flow	-$3.5B	-$3.7B-68.8%	-$2.2B-22.9%	-$1.8B-77.4%	-$1.0B-0.3%	-$1.0B+49.0%	-$2.0B-681.6%	-$252.1M-227.0%	-$77.1M-216.0%	-$24.4M+96.5%	-$700.5M-166.6%	-$262.8M-20.2%	-$218.5M-402.7%	$72.2M+173.9%	-$97.6M-125.4%	$384.2M
Dividends Paid	$378.5M	$370.3M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$3.3B	$3.4B+32.1%	$2.6B+16.5%	$2.2B+7.3%	$2.1B+26.6%	$1.6B-71.9%	$5.8B+2019.2%	$275.9M+6170.5%	$4.4M	$0	$0	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$813.0M-29.0%	$1.1B+3.2%	$1.2B-7.3%	$1.6B+25.4%	$1.1B+223.3%	$1.0B-30.9%	$1.3B+15.9%	$1.3B+15.9%
Depreciation & Amortization	$123.7M-8.4%	$123.2M-2.9%	$145.0M+14.7%	$136.7M+12.3%	$135.1M+11.9%	$126.9M+11.2%	$126.4M+11.9%	$121.7M+15.5%
Stock-Based Compensation	N/A	$257.4M+0.7%	N/A	N/A	N/A	$255.7M+11.1%	N/A	N/A
Capital Expenditures	$240.2M+9.7%	$230.6M+0.6%	$248.7M+24.6%	$201.4M-16.7%	$219.0M+21.3%	$229.3M+71.2%	$199.6M-20.6%	$241.9M+37.4%
Free Cash Flow	$572.8M-38.1%	$848.3M+4.0%	$922.0M-13.3%	$1.4B+35.1%	$925.4M+433.4%	$815.8M-40.8%	$1.1B+26.8%	$1.0B+11.8%
Investing Cash Flow	-$92.7M+91.5%	-$428.9M-166.2%	$220.3M-37.2%	-$402.9M+29.9%	-$1.1B-96.3%	$647.5M+138.4%	$350.6M+629.6%	-$574.4M-15.7%
Financing Cash Flow	-$1.2B-8.5%	-$802.2M+26.3%	-$780.1M+31.3%	-$717.9M-13.2%	-$1.1B-136.0%	-$1.1B-2412.5%	-$1.1B-154.5%	-$634.0M-55.7%
Dividends Paid	$96.8M+4.5%	$97.8M+4.3%	$92.7M	$91.2M	$92.6M	$93.8M	$0	$0
Share Buybacks	$1.2B+10.2%	$794.3M-23.7%	$671.7M-31.0%	$664.0M-9.7%	$1.1B+75.8%	$1.0B+257.5%	$973.0M+236.7%	$735.1M+34.5%

REGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REGN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	93.9%-1.5pp	95.4%-1.2pp	96.5%+0.6pp	96.0%+1.9pp	94.1%-1.3pp	95.4%+1.0pp	94.4%+0.5pp	93.9%-5.1pp	99.1%
Operating Margin	24.9%-3.2pp	28.1%-2.7pp	30.9%-8.1pp	38.9%-16.7pp	55.7%+13.6pp	42.1%+8.4pp	33.7%-15.5pp	49.3%+13.8pp	35.4%+8.0pp	27.4%-3.1pp	30.5%+1.3pp	29.2%-6.1pp	35.3%+2.1pp	33.2%+79.2pp	-46.0%
Net Margin	31.4%+0.3pp	31.1%+0.9pp	30.1%-5.5pp	35.6%-14.6pp	50.2%+8.9pp	41.3%+9.1pp	32.3%-15.2pp	47.5%+27.1pp	20.4%+2.0pp	18.4%+2.9pp	15.5%+3.5pp	12.0%-7.7pp	19.7%-34.8pp	54.4%+104.2pp	-49.7%
Return on Equity	14.4%-0.6pp	15.0%-0.2pp	15.2%-3.9pp	19.1%-23.9pp	43.0%+11.2pp	31.9%+12.8pp	19.1%-8.8pp	27.9%+8.4pp	19.5%-0.6pp	20.1%+2.7pp	17.4%+4.1pp	13.3%-7.8pp	21.1%-38.6pp	59.7%+105.4pp	-45.6%
Return on Assets	11.1%-0.6pp	11.7%-0.3pp	11.9%-2.9pp	14.8%-16.9pp	31.8%+11.3pp	20.5%+6.2pp	14.3%-6.5pp	20.8%+7.2pp	13.7%+0.8pp	12.8%+1.5pp	11.3%+2.5pp	8.8%-5.2pp	14.0%-22.0pp	36.1%+52.8pp	-16.8%
Current Ratio	4.13-0.6x	4.73-1.0x	5.69+0.6x	5.06+1.5x	3.56-0.1x	3.630.0x	3.67-0.8x	4.47+0.7x	3.82+1.3x	2.56-1.0x	3.59+0.4x	3.18-2.8x	6.01-1.4x	7.37+2.9x	4.49
Debt-to-Equity	0.060.0x	0.070.0x	0.080.0x	0.090.0x	0.11-0.1x	0.18+0.2x	0.00-0.3x	0.34-0.1x	0.43-0.1x	0.570.0x	0.530.0x	0.500.0x	0.51-0.2x	0.66-1.1x	1.72
Asset Turnover	0.350.0x	0.380.0x	0.400.0x	0.42-0.2x	0.63+0.1x	0.50+0.1x	0.440.0x	0.44-0.2x	0.670.0x	0.700.0x	0.730.0x	0.730.0x	0.71+0.1x	0.66+0.3x	0.34
FCF Margin	28.4%+2.6pp	25.8%-3.7pp	29.5%-6.8pp	36.4%-4.3pp	40.6%+17.0pp	23.6%-6.9pp	30.5%-4.7pp	35.2%+17.6pp	17.6%-2.4pp	20.0%+4.1pp	15.9%+1.0pp	14.9%-5.7pp	20.5%+29.5pp	-9.0%+35.6pp	-44.6%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	30.1%+0.8pp	17.8%-1.7pp	22.7%-3.5pp	27.4%-4.3pp	29.4%-0.8pp	19.5%-4.4pp	26.1%-2.2pp	31.7%-1.3pp
Net Margin	30.2%-7.6pp	20.2%-6.5pp	21.7%-2.5pp	38.9%+2.9pp	37.9%-2.5pp	26.7%+3.7pp	24.2%-9.6pp	36.0%+6.1pp
Return on Equity	4.1%-0.6pp	2.3%-0.4pp	2.7%-0.4pp	4.7%+0.2pp	4.7%-0.4pp	2.8%+0.1pp	3.1%-1.3pp	4.6%+0.5pp
Return on Assets	3.1%-0.5pp	1.8%-0.4pp	2.1%-0.3pp	3.6%+0.1pp	3.6%-0.3pp	2.1%0.0pp	2.4%-1.1pp	3.6%+0.4pp
Current Ratio	3.34-1.3x	3.56-1.4x	4.13-0.6x	4.06-1.2x	4.60-0.8x	4.93-0.3x	4.73-1.0x	5.28+0.1x
Debt-to-Equity	0.060.0x	0.060.0x	0.060.0x	0.060.0x	0.070.0x	0.070.0x	0.070.0x	0.070.0x
Asset Turnover	0.100.0x	0.090.0x	0.100.0x	0.090.0x	0.100.0x	0.080.0x	0.100.0x	0.100.0x
FCF Margin	13.4%-11.8pp	23.5%-3.4pp	23.7%-4.3pp	37.8%+9.6pp	25.2%+20.3pp	26.9%-16.9pp	28.1%+3.7pp	28.2%+0.3pp

Not reported in any period shown, so not listed: Gross Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Regeneron Pharmaceuticals Inc REGN	FY2025	$14.3B	$4.5B	31.4%	$76.1B	78/100
Alnylam Pharmaceuticals, Inc. ALNY	FY2025	$3.7B	$313.7M	8.5%	$30.0B	51/100
argenx SE ARGX	FY2025	$4.2B	$1.3B	30.4%	$58.4B	43/100
BeOne Medicines Ltd. ONC	FY2025	$5.3B	$286.9M	5.4%	$41.2B	57/100
Vertex Pharmaceuticals Inc VRTX	FY2025	$12.0B	$4.0B	32.9%	$128.2B	74/100
Insmed, Inc. INSM	FY2025	$606.4M	-$1.3B	N/A	$22.2B	51/100

Where Regeneron Pharmaceuticals Inc Ranks

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc's annual revenue?

Regeneron Pharmaceuticals Inc (REGN) reported $14.3B in total revenue for fiscal year 2025. This represents a 1.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Regeneron Pharmaceuticals Inc's revenue growing?

Regeneron Pharmaceuticals Inc (REGN) revenue grew by 1.0% year-over-year, from $14.2B to $14.3B in fiscal year 2025.

Is Regeneron Pharmaceuticals Inc profitable?

Yes, Regeneron Pharmaceuticals Inc (REGN) reported a net income of $4.5B in fiscal year 2025, with a net profit margin of 31.4%.

What is Regeneron Pharmaceuticals Inc's EBITDA?

Regeneron Pharmaceuticals Inc (REGN) had EBITDA of $4.1B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Regeneron Pharmaceuticals Inc have?

As of fiscal year 2025, Regeneron Pharmaceuticals Inc (REGN) had $3.1B in cash and equivalents against $2.0B in long-term debt.

What is Regeneron Pharmaceuticals Inc's operating margin?

Regeneron Pharmaceuticals Inc (REGN) had an operating margin of 24.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Regeneron Pharmaceuticals Inc's net profit margin?

Regeneron Pharmaceuticals Inc (REGN) had a net profit margin of 31.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Regeneron Pharmaceuticals Inc's return on equity (ROE)?

Regeneron Pharmaceuticals Inc (REGN) has a return on equity of 14.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Regeneron Pharmaceuticals Inc's free cash flow?

Regeneron Pharmaceuticals Inc (REGN) generated $4.1B in free cash flow during fiscal year 2025. This represents a 11.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Regeneron Pharmaceuticals Inc's operating cash flow?

Regeneron Pharmaceuticals Inc (REGN) generated $5.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Regeneron Pharmaceuticals Inc's total assets?

Regeneron Pharmaceuticals Inc (REGN) had $40.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Regeneron Pharmaceuticals Inc's capital expenditures?

Regeneron Pharmaceuticals Inc (REGN) invested $898.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Regeneron Pharmaceuticals Inc spend on research and development?

Regeneron Pharmaceuticals Inc (REGN) invested $5.9B in research and development during fiscal year 2025.

Does Regeneron Pharmaceuticals Inc buy back shares?

Yes, Regeneron Pharmaceuticals Inc (REGN) spent $3.4B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Regeneron Pharmaceuticals Inc's current ratio?

Regeneron Pharmaceuticals Inc (REGN) had a current ratio of 4.13 as of fiscal year 2025, which is generally considered healthy.

What is Regeneron Pharmaceuticals Inc's debt-to-equity ratio?

Regeneron Pharmaceuticals Inc (REGN) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Regeneron Pharmaceuticals Inc's return on assets (ROA)?

Regeneron Pharmaceuticals Inc (REGN) had a return on assets of 11.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Regeneron Pharmaceuticals Inc's P/E ratio?

Regeneron Pharmaceuticals Inc (REGN) trades at 17.6x earnings, its market capitalization divided by net income of $4.3B net income, trailing 12 months to June 30, 2026. The market capitalization is $76.1B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Regeneron Pharmaceuticals Inc's price-to-sales ratio?

Regeneron Pharmaceuticals Inc (REGN) trades at 4.9x sales, its market capitalization divided by revenue of $15.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $76.1B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Regeneron Pharmaceuticals Inc's Altman Z-Score?

Regeneron Pharmaceuticals Inc (REGN) has an Altman Z-Score of 7.20, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Regeneron Pharmaceuticals Inc's Piotroski F-Score?

Regeneron Pharmaceuticals Inc (REGN) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Regeneron Pharmaceuticals Inc's earnings high quality?

Regeneron Pharmaceuticals Inc (REGN) has an earnings quality ratio of 1.11x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Regeneron Pharmaceuticals Inc cover its interest payments?

Regeneron Pharmaceuticals Inc (REGN) has an interest coverage ratio of 81.69x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Regeneron Pharmaceuticals Inc?

Regeneron Pharmaceuticals Inc (REGN) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.